167 related articles for article (PubMed ID: 29213478)
1. Some aspects of the validity of the Montreal Cognitive Assessment (MoCA) for evaluating cognitive impairment in Brazilian patients with Parkinson's disease.
Tumas V; Borges V; Ballalai-Ferraz H; Zabetian CP; Mata IF; Brito MMC; Foss MP; Novaretti N; Santos-Lobato BL
Dement Neuropsychol; 2016; 10(4):333-338. PubMed ID: 29213478
[TBL] [Abstract][Full Text] [Related]
2. Validation of a novel Montreal Cognitive Assessment scoring algorithm in non-demented Parkinson's disease patients.
Sulzer P; Becker S; Maetzler W; Kalbe E; van Nueten L; Timmers M; Machetanz G; Streffer J; Salvadore G; Scholz E; Tkaczynska Z; Brockmann K; Berg D; Liepelt-Scarfone I
J Neurol; 2018 Sep; 265(9):1976-1984. PubMed ID: 29936665
[TBL] [Abstract][Full Text] [Related]
3. Cut-off points of the Portuguese version of the Montreal Cognitive Assessment for cognitive evaluation in Parkinson's disease.
Almeida KJ; Carvalho LCLS; Monteiro THOH; Gonçalves PCJ; Campos-Sousa RN
Dement Neuropsychol; 2019; 13(2):210-215. PubMed ID: 31285796
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment.
Samat NA; Abdul Murad NA; Mohamad K; Abdul Razak MR; Mohamed Ibrahim N
Front Neurosci; 2017; 11():712. PubMed ID: 29326545
[No Abstract] [Full Text] [Related]
5. Validity and diagnostics of the Italian version of the Montreal Cognitive Assessment (MoCA) in non-demented Parkinson's disease patients.
D'Iorio A; Aiello EN; Amboni M; Vitale C; Verde F; Silani V; Ticozzi N; Ciammola A; Poletti B; Santangelo G
Aging Clin Exp Res; 2023 Oct; 35(10):2157-2163. PubMed ID: 37480503
[TBL] [Abstract][Full Text] [Related]
6. Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.
Faust-Socher A; Duff-Canning S; Grabovsky A; Armstrong MJ; Rothberg B; Eslinger PJ; Meaney CA; Schneider RB; Tang-Wai DF; Fox SH; Zadikoff C; Kennedy N; Chou KL; Persad C; Litvan I; Mast BT; Gerstenecker AT; Weintraub S; Reginold W; Marras C
Dement Geriatr Cogn Disord; 2019; 47(4-6):187-197. PubMed ID: 31315127
[TBL] [Abstract][Full Text] [Related]
7. White matter damage in patients with mild cognitive impairment in Parkinson's disease.
Li QQ; Wu K; Xu JL; Yin L
Quant Imaging Med Surg; 2022 Feb; 12(2):1290-1298. PubMed ID: 35111624
[TBL] [Abstract][Full Text] [Related]
8. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score.
Nazem S; Siderowf AD; Duda JE; Have TT; Colcher A; Horn SS; Moberg PJ; Wilkinson JR; Hurtig HI; Stern MB; Weintraub D
J Am Geriatr Soc; 2009 Feb; 57(2):304-8. PubMed ID: 19170786
[TBL] [Abstract][Full Text] [Related]
9. Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.
Badrkhahan SZ; Sikaroodi H; Sharifi F; Kouti L; Noroozian M
Appl Neuropsychol Adult; 2020; 27(5):431-439. PubMed ID: 30821505
[TBL] [Abstract][Full Text] [Related]
10. The MMSE and MoCA for Screening Cognitive Impairment in Less Educated Patients with Parkinson's Disease.
Kim JI; Sunwoo MK; Sohn YH; Lee PH; Hong JY
J Mov Disord; 2016 Sep; 9(3):152-9. PubMed ID: 27667187
[TBL] [Abstract][Full Text] [Related]
11. Predictors of cognitive impairment in an early stage Parkinson's disease cohort.
Hu MT; Szewczyk-Królikowski K; Tomlinson P; Nithi K; Rolinski M; Murray C; Talbot K; Ebmeier KP; Mackay CE; Ben-Shlomo Y
Mov Disord; 2014 Mar; 29(3):351-9. PubMed ID: 24395708
[TBL] [Abstract][Full Text] [Related]
12. Psychometric properties and construct validity of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS) in Colombia.
Clavijo-Moran HJC; Álvarez-García D; Pinilla-Monsalve GD; Muñoz-Ospina B; Orozco J
Front Psychol; 2022; 13():1018176. PubMed ID: 36533029
[TBL] [Abstract][Full Text] [Related]
13. Screening for Cognitive Impairment in Parkinson's Disease: Improving the Diagnostic Utility of the MoCA through Subtest Weighting.
Fengler S; Kessler J; Timmermann L; Zapf A; Elben S; Wojtecki L; Tucha O; Kalbe E
PLoS One; 2016; 11(7):e0159318. PubMed ID: 27437705
[TBL] [Abstract][Full Text] [Related]
14. Floor and ceiling effects on the Montreal Cognitive Assessment in patients with Parkinson's disease in Brazil.
Koshimoto BHB; Brandão PRP; Borges V; Ferraz HB; Schumacher-Schuh AF; Rieder CRM; Olchik MR; Mata IF; Tumas V; Santos-Lobato BL
Dement Neuropsychol; 2023; 17():e20230022. PubMed ID: 38053643
[TBL] [Abstract][Full Text] [Related]
15. A subtest analysis of the Montreal cognitive assessment (MoCA): which subtests can best discriminate between healthy controls, mild cognitive impairment and Alzheimer's disease?
Cecato JF; Martinelli JE; Izbicki R; Yassuda MS; Aprahamian I
Int Psychogeriatr; 2016 May; 28(5):825-32. PubMed ID: 26620850
[TBL] [Abstract][Full Text] [Related]
16. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson's disease.
Kandiah N; Zhang A; Cenina AR; Au WL; Nadkarni N; Tan LC
Parkinsonism Relat Disord; 2014 Nov; 20(11):1145-8. PubMed ID: 25176439
[TBL] [Abstract][Full Text] [Related]
17. Cognitive profile and determinants of poor cognition in people without dementia in Parkinson's disease.
Barnish M; Daley DJ; Deane KH; Clark AB; Gray RJ; Horton SM; Butterfint ZR; Myint PK
Med J Islam Repub Iran; 2019; 33():1. PubMed ID: 31086780
[No Abstract] [Full Text] [Related]
18. Comparison of Mini-Mental State Examination and Montreal Cognitive Assessment Ratings Across Levels of Parkinson's Disease Severity.
Snyder A; Gruber-Baldini AL; Rainer von Coelln F; Savitt JM; Reich SG; Armstrong MJ; Shulman LM
J Parkinsons Dis; 2021; 11(4):1995-2003. PubMed ID: 34366371
[TBL] [Abstract][Full Text] [Related]
19. Determining a Short Form Montreal Cognitive Assessment (s-MoCA) Czech Version: Validity in Mild Cognitive Impairment Parkinson's Disease and Cross-Cultural Comparison.
Bezdicek O; Červenková M; Moore TM; Stepankova Georgi H; Sulc Z; Wolk DA; Weintraub DA; Moberg PJ; Jech R; Kopecek M; Roalf DR
Assessment; 2020 Dec; 27(8):1960-1970. PubMed ID: 29929376
[TBL] [Abstract][Full Text] [Related]
20. Validation of Montreal Cognitive Assessment and Discriminant Power of Montreal Cognitive Assessment Subtests in Patients With Mild Cognitive Impairment and Alzheimer Dementia in Turkish Population.
Kaya Y; Aki OE; Can UA; Derle E; Kibaroğlu S; Barak A
J Geriatr Psychiatry Neurol; 2014 Jun; 27(2):103-9. PubMed ID: 24578463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
